autologous anti-CD19 CAR T-cells / University Hospital Center of Montpellier - LARVOL DELTA

SCLEROCAR: Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (clinicaltrials.gov) - P2 | N=6 | Not yet recruiting | Sponsor: University Hospital, Montpellier | Trial completion date: Apr 2028 ➔ Aug 2028 | Initiation date: Apr 2026 ➔ Aug 2026 | Trial primary completion date: Apr 2026 ➔ Aug 2026

Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Scleroderma • Systemic Sclerosis

SCLEROCAR: Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (clinicaltrials.gov) - P2 | N=6 | Active, not recruiting | Sponsor: University Hospital, Montpellier | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Scleroderma • Systemic Sclerosis

SCLEROCAR: Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (clinicaltrials.gov) - P2 | N=6 | Recruiting | Sponsor: University Hospital, Montpellier | Not yet recruiting ➔ Recruiting | Trial primary completion date: Aug 2026 ➔ Jun 2028

Enrollment open • Trial primary completion date • Immunology • Scleroderma • Systemic Sclerosis

SCLEROCAR: Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (clinicaltrials.gov) - P2 | N=6 | Not yet recruiting | Sponsor: University Hospital, Montpellier

New P2 trial • Immunology • Scleroderma • Systemic Sclerosis

SCLEROCAR: Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy (clinicaltrials.gov) - P2 | N=6 | Recruiting | Sponsor: University Hospital, Montpellier | Active, not recruiting ➔ Recruiting

Enrollment open • Immunology • Scleroderma • Systemic Sclerosis